ExpreS2ion Biotech Holding AB (EXPRS2) - Total Liabilities
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has total liabilities worth Skr23.98 Million SEK (≈ $2.58 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EXPRS2 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
ExpreS2ion Biotech Holding AB - Total Liabilities Trend (2013–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ExpreS2ion Biotech Holding AB (EXPRS2) total assets.
ExpreS2ion Biotech Holding AB Competitors by Total Liabilities
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infield Minerals Corp
V:INFD
|
Canada | CA$195.42K |
|
CO2 Gro Inc
V:GROW
|
Canada | CA$473.23K |
|
India Capital Growth Fund
LSE:IGC
|
UK | GBX2.13 Million |
|
Charles & Colvard Ltd
NASDAQ:CTHR
|
USA | $15.33 Million |
|
RED LAKE GOLD INC.
F:P11A
|
Germany | €38.30K |
|
Rapid Nutrition PLC
PA:ALRPD
|
France | €403.84K |
|
Savannah Energy PLC
LSE:SAVE
|
UK | GBX1.33 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down ExpreS2ion Biotech Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ExpreS2ion Biotech Holding AB (EXPRS2) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ExpreS2ion Biotech Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ExpreS2ion Biotech Holding AB (2013–2025)
The table below shows the annual total liabilities of ExpreS2ion Biotech Holding AB from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr29.42 Million ≈ $3.17 Million |
-26.65% |
| 2024-12-31 | Skr40.11 Million ≈ $4.32 Million |
+200.95% |
| 2023-12-31 | Skr13.33 Million ≈ $1.43 Million |
-60.84% |
| 2022-12-31 | Skr34.04 Million ≈ $3.66 Million |
+193.16% |
| 2021-12-31 | Skr11.61 Million ≈ $1.25 Million |
-52.24% |
| 2020-12-31 | Skr24.31 Million ≈ $2.62 Million |
+22.86% |
| 2019-12-31 | Skr19.79 Million ≈ $2.13 Million |
+56.37% |
| 2018-12-31 | Skr12.65 Million ≈ $1.36 Million |
+20.53% |
| 2017-12-31 | Skr10.50 Million ≈ $1.13 Million |
-10.54% |
| 2016-12-31 | Skr11.73 Million ≈ $1.26 Million |
+16.19% |
| 2015-12-31 | Skr10.10 Million ≈ $1.09 Million |
+222.22% |
| 2014-12-31 | Skr3.13 Million ≈ $337.34K |
+44.07% |
| 2013-12-31 | Skr2.18 Million ≈ $234.15K |
-- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more